The most frequently observed clinically significant adverse events associated with TAS-@ were neutropenia , which occurred in @ % of those treated , and leukopenia , which occurred in @ % ; @ % of the patients who received TAS-@ had febrile neutropenia , and one death related to TAS-@ was reported .